Clinical trial · Interventional
Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Multiple myeloma (MM) is the most common bone marrow malignancy of terminally differentiated plasma cells. It accounts for about 1% of all malignant diseases and 10% of haematological malignancies and takes the second place after non-Hodgkin lymphoma . There are some serological and clinical criteria that help to detect the stage of MM and predict the patients' prognosis. These criteria include the level of M protein, calcium, haemoglobin, albumin, creatinine, β2-microglobulin and glomerular filtration rate (GFR).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biochemical and heamatological tests | Diagnostic Test | — | UNRESOLVED |
| Bone marow biopsy and aspiration | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- diagnostic group
- interventionNames
- Procedure: Bone marow biopsy and aspiration
- Diagnostic Test: biochemical and heamatological tests
Primary outcomes (1)
- measure
- Cycline D1 expression in bone marrow biopsy of multiple myeloma patient
- timeFrame
- 1 year
- description
- Cycline D1 expression in bone marrow biopsy of multiple myeloma patient
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients older than 18 year with newly diagnosed MM. 2. Approval to sign an informed written consent. Exclusion Criteria: * 1\. Patient younger than 18 years. 2.Refusal to sign an informed written consent.
References
Publications (0)
Data not yet available